Dr. Hirsch is the Executive Director of the MIT Center for Biomedical Innovation (CBI) where she leads NEWDIGS (NEW Drug Development ParadIGmS; see http://newdigs.mit.edu), a “think and do tank” that is re-engineering pharmaceutical innovation to reliably and sustainably deliver new, better, affordable therapeutics to the right patients, faster. NEWDIGS’ flagship project on “Adaptive Biomedical Innovation” (ABI) helped inspire the successful EU-wide Adaptive Pathways pilot program led by the European Medicines Agency (2014-2016).  Under Dr. Hirsch’s leadership, NEWDIGS continues to channel multi-stakeholder thought leadership to advance other critical enablers of ABI such as “precision financing” models for durable and potentially curative therapies, structured evidence planning and production across the product lifecycle and disease focused “learning ecosystems.”

Dr. Hirsch has held a number of leadership roles that leverage her broad clinical background (Internal Medicine, Emergency Medicine, and Psychiatry) both in industry (Millennium Pharmaceuticals) as well as academia (Harvard, Brown, and Tufts).